偏头痛患者畏光与干涩感独立于基线泪液量,且肉毒毒素A注射后改善
该回顾性研究纳入76例慢性偏头痛患者,评估肉毒毒素A(BoNT-A)对畏光和干眼症状的疗效及泪液量的作用。结果发现注射前偏头痛、畏光和干眼症状评分显著相关(p<0.05),但均与基线酚红棉线试验泪液量无关;BoNT-A注射后畏光显著改善,基线干眼症状严重者(DEQ-5≥12)干眼症状亦显著改善(p=0.027),且症状改善与基线泪液量无关。
要点
- BoNT-A可显著改善慢性偏头痛患者的畏光症状。
- 基线干眼症状严重者(DEQ-5≥12)注射后干眼症状显著改善。
- 畏光与干眼症状均与基线泪液量无关。
核心结论
- BoNT-A显著改善偏头痛患者的畏光,且对基线干眼症状严重者的干眼症状有改善,独立于基线泪膜量。
研究设计与样本
- 回顾性研究,纳入2017年8月23日至12月13日在迈阿密退伍军人医疗中心神经毒素门诊因慢性偏头痛接受BoNT-A治疗的76例患者。
主要发现
- 注射前偏头痛、畏光和干眼症状评分均显著相关(p<0.05),且均与注射前酚红棉线试验结果无关。
- BoNT-A注射后偏头痛、畏光和干眼症状的改善也显著相关(p<0.05),同样与注射前酚红棉线试验结果无关。
- BoNT-A注射后畏光评分显著改善;基线干眼症状严重者(DEQ-5评分≥12)干眼症状显著改善(p=0.027)。
- 在全部有干眼症状者(DEQ-5≥6)的logistic回归分析中,干眼症状更严重者更可能改善(OR 1.27,95%CI 1.06至1.51,p<0.01)。
关键数值与推荐
- 干眼症状严重定义为基线DEQ-5评分≥12。
- 有干眼症状定义为DEQ-5评分≥6。
- 干眼症状更严重者改善的OR为1.27(95%CI 1.06至1.51,p<0.01)。
临床怎么用
- 对慢性偏头痛患者,BoNT-A治疗可能同时改善畏光和严重干眼症状,且疗效不依赖基线泪液量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the efficacy of botulinum toxin A (BoNT-A) in reducing photophobia and dry eye symptoms in individuals with chronic migraine. Additionally, we aimed to evaluate tear film volume as a potential contributor to symptoms in these patients. METHODS: Retrospective review of 76 patients who received BoNT-A for chronic migraine between 23 August 2017 and 13 December 2017 at the Miami Veterans Affairs Medical Center Neurotoxin Clinic. Demographic data and all comorbidities were queried via chart review. Standardised validated surveys were administered to assess symptoms prior to and after BoNT-A injection. Preinjection tear volumes were obtained using the phenol red thread (PRT) test. RESULTS: Preinjection migraine, photophobia and dry eye symptom scores were all significantly correlated, p<0.05, and none were associated with preinjection PRT results. After BoNT-A, improvements in migraine, photophobia and dry eye symptoms were also significantly correlated, p<0.05 and similarly did not associate with preinjection PRT results. Photophobia scores significantly improved following BoNT-A, while dry eye symptoms significantly improved in those with severe symptoms at baseline (DEQ-5 score ≥12), p=0.027. In logistic regression analysis of all individuals with dry eye symptoms (DEQ-5 ≥6), individuals with more severe dry eye symptoms were more likely improve, OR 1.27, 95% CI 1.06 to 1.51, p<0.01. CONCLUSIONS: BoNT-A significantly improved photophobia in patients being treated for migraine and also improved dry eye symptoms in patients with severe symptoms at baseline, independent of baseline tear film volume. These improvements may be due to modulation of shared trigeminal neural pathways.
引用
- Diel RJ, Hwang J, Kroeger ZA, et al. Photophobia and sensations of dryness in patients with migraine occur independent of baseline tear volume and improve following botulinum toxin A injections. Br J Ophthalmol. 2018. PMID: 30269099. doi:10.1136/bjophthalmol-2018-312649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。